



Advances in Influenza Virus Vaccines

Guest Editors:

Dr. George Kassianos

**Prof. Dr. Raul Ortiz De
Lejarazu**

Dr. Iván Sanz Muñoz

Dr. Ivan Aloysius

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editors

The current pandemic has greatly accelerated advances in vaccine research and production. The question that emerges at this point, however, is: Will these advances in vaccinology benefit other infectious diseases, other than COVID-19?

In recent years, we have witnessed improvements in existing influenza vaccine technologies aiming to overcome problems such as possible egg adaptation and immunosenescence, triggered mainly by lower effectiveness of influenza vaccines against the A/H3N2 influenza virus.

This Special Issue of *Vaccines* on “Advances in Influenza Virus Vaccines” aims to bring together the work of scientists that aim to further improve influenza vaccine technology in order to bring about greater vaccine effectiveness. Research as well as opinion papers are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)